A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Phase 2

Withdrawn

• Conditions: Solid Tumors
• Interventions: Drug: Atezolizumab; Drug: Tiragolumab

• Registration Number: NCT06331598
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This study is being conducted to evaluate efficacy parameters (disease free survival \[DFS\] and overall survival \[OS\]) of atezolizumab and atezolizumab in combination with tiragolumab in TMB-H or MSI-H as adjuvant treatment after standard radical intended treatment in participants with intermediate-high risk of recurrence.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2024-03-19
• Study First Submitted QC: 2024-03-19
• Study First Posted: 2024-03-26
• Study Start: 2024-11-30
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-19
• Last Update Posted: 2024-12-24
• Primary Completion: 2028-10-20
• Study Completion: 2029-09-20

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
• Any of the following solid tumors considered to be resectable with a curative intent: non-small cell lung cancer, skin melanoma, skin squamous cell carcinoma, urothelial carcinoma, colorectal cancer, gastric cancer, endometrial cancer, cervix cancer, head and neck cancer and any other tumor type with known high TMB (≥ 13 mut/MB) or MSI-H
• Participants must undergo standard treatment according to the stage of their disease and investigator´s choice
• All participants must be disease free after standard therapy to be included in this study
• Having TMB ≥ 13 mut/MB or MSI-H in tumor tissue biopsy obtained prior to starting standard treatment or from surgical specimens and analyzed using F1 CDx
• Participants must be at intermediate/high risk of recurrence
• Adequate hematologic and organ function
• Female participants of childbearing potential and male participants with female partners of childbearing potential must be willing to avoid pregnancy
• Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 8 days prior to initiation of study drug.

Exclusion Criteria

• Previous malignancies within 3 years prior to enrollment, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
• Prior cancer immunotherapy
• Women who are pregnant, lactating, or intending to become pregnant during the study
• History of autoimmune disease
• History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
• Significant cardiovascular disease
• Treatment with systemic immunosuppressive medications within 2 weeks prior to inclusion
• Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug-elimination half-lives of the drug, whichever is longer, prior to randomization.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Atezolizumab + Tiragolumab	Tiragolumab	Participants will be treated with atezolizumab and tiragolumab Q4W for 12 cycles (cycle = 28 days). After study treatment discontinuation participants will be followed until disease progression and afterwards, information on survival follow-up and new anti-cancer therapy will be collected until death (unless the participant withdraws consent, is lost to follow-up or the Sponsor terminates the study).
Atezolizumab	Atezolizumab	Participants will be treated with atezolizumab every 4 weeks (Q4W) for 12 cycles (cycle = 28 days). After study treatment discontinuation participants will be followed until disease progression and afterwards, survival follow-up and new anti-cancer therapy will be collected until death (unless the participant withdraws consent, is lost to follow-up or the Sponsor terminates the study).
Atezolizumab + Tiragolumab	Atezolizumab	Participants will be treated with atezolizumab and tiragolumab Q4W for 12 cycles (cycle = 28 days). After study treatment discontinuation participants will be followed until disease progression and afterwards, information on survival follow-up and new anti-cancer therapy will be collected until death (unless the participant withdraws consent, is lost to follow-up or the Sponsor terminates the study).

Primary Outcome Measures

Name	Time	Method
Disease Free Survival (DFS) Rate at 24 Months	Month 24

Secondary Outcome Measures

Name	Time	Method
DFS Rate at 36, 48 and 60 Months	Months 36, 48, 60
OS (Overall Survival)	From randomization to death from any cause (up to approximately 60 months)
Percentage of Participants With Adverse Events	Up to approximately 60 months

Trial Locations

Locations (3)

Hospital Universitario Virgen; Servicio de Oncologia; 🇪🇸 Sevilla, Spain

Hospital Universitari Vall dHebron; Oncology; 🇪🇸 Barcelona, Spain

Hospital Universitario 12 de Octubre; Servicio de Oncologia; 🇪🇸 Madrid, Spain